P-143 Lack of expression of CDX2: Prognostic biomarker in stage IV colorectal cancer

Soares, A.; Rodrigues, Denise Celeste Godoy de Andrade; Cipriano, Elia; Tavares, A.; Vilaca, M.; Silva, D.; Santos, Joana Dos; Mesquita, Anabela; Salgado, M.; Sottomayor, C.; Almeida, Rafael Fernandes

doi:10.1016/j.annonc.2020.04.225

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with CDX2-negative tumours additionally had a faster progression on first-line treatment than those with tumours that expressed CDX2. Lack of CDX2 was a poor prognostic factor for mCRC in other retrospective studies [ 1 , 5 , 46 , 54 , 55 ].…”

Section: Discussionmentioning

confidence: 73%

oss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer

Caldas,

Nunes,

Taboada

et al. 2024

ecancer Journal

View full text Add to dashboard Cite

Lack of expression of the tumour suppressor gene caudal-type homeobox 2 (CDX2) associates with poor outcomes in early stage colorectal cancer (CRC). Yet its prognostic value in the context of other prognostic biomarkers in metastatic CRC (mCRC) is unknown. Overexpressed cyclooxygenase-2 (COX2) has been reported in advanced CRC. However, CDX2 and COX2 relationship in mCRC remains undetermined. We aimed to assess their expression in mCRC tumours from a clinically characterised cohort and their influence on overall survival (OS) and progression-free survival (PFS) in first line. Among 720 consecutive mCRC patients, 346 had tumour samples appropriate for tissue microarray assembly and immunohistochemistry analyses. Clinical and survival data were retrospectively assessed. Loss of CDX2 expression was detected in 27 (7.8%) samples, enriched in poorly differentiated tumours (20%; p < 0.01) and in those with the BRAF p.V600E variant (40%; p < 0.01). Most tumours (93.4%) expressed COX2. COX2-negative samples were enriched in poorly differentiated mCRC. In unadjusted analyses, median OS (p < 0.001) and median PFS (p < 0.05) were inferior for patients with CDX2-negative versus CDX2positive tumours. In conclusion, loss of CDX2 was significantly associated with poorly differentiated mCRC and BRAF p.V600E allele and a prognostic marker of worse OS.

show abstract